FDA advisers vote to back six of seven peptides, over the agency's objections

What the panel decided

Over July 23 and 24, the panel voted to recommend six of the seven peptides for the 503A compounding list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. Only emideltide was voted down. Every recommendation is advisory and non-binding, and the FDA decides separately whether to adopt any of them.

The FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 at the agency's White Oak campus in Silver Spring, Maryland, under docket FDA-2025-N-6895 [1]. The committee is a standing panel of outside experts that reviews evidence and votes on recommendations. It does not write regulations, and its vote does not change the law by itself. Across the two days it reviewed seven peptides, one at a time, and recommended six of them for the 503A bulk drug substances list [7].

On Thursday, July 23, the committee voted to recommend BPC-157, KPV, TB-500 and MOTS-c [11]. On Friday, July 24, it also recommended epitalon and semax, and voted down emideltide (a sleep-related peptide also called DSIP), the only one of the seven the panel declined to back [7].

The margins are worth stating carefully, because most of them were never published. TIME reported the only per-substance tally from the Thursday: on BPC-157, eight members voted yes, six voted no and one abstained. It also reported the emideltide vote, which failed 6 to 7 [12]. The Associated Press reported that the panel voted 8 to 6 with one abstention across several of Thursday's votes, as a generalization rather than a substance-by-substance breakdown [8]. No margin was reported for KPV, TB-500, MOTS-c, epitalon or semax, so anyone quoting one for those five is quoting a number that does not exist. What is certain is the outcome: all five were recommended.

The number that matters most is not any single tally but who it went against. As the sections below detail, the FDA's own reviewers had recommended in writing against adding all seven, so on six of them the panel overruled its own agency's scientists [12]. Reporting on the votes noted that the yes side was carried largely by the members the FDA added to the panel ahead of the meeting, most of whom have ties to the peptide industry, while the members with academic backgrounds mostly voted no [7][8].

What none of this did is make any peptide legal. A favourable vote is a recommendation, not a decision: it does not add a substance to the list, does not make it an approved drug, and does not change what a pharmacy may compound today. It hands the FDA advice the agency can accept, modify or reject, and even acceptance then runs through formal rulemaking that takes many months. If those names look familiar, it is because several are ones we teach in depth, and a second meeting scheduled before the end of February 2027 will take up five more, including GHK-Cu, dihexa, melanotan II and LL-37 [3].

What the committee is actually voting on

The question is narrow: should each peptide be added to the 503A bulk drug substances list? That list names raw ingredients a compounding pharmacy may legally use to make a custom preparation for a specific patient. It is not drug approval, and it is not a safety endorsement.

This is the part most coverage skips, and it is where nearly all the confusion comes from. The vote is about the 503A bulk drug substances list, usually shortened to "the 503A bulks list" [3].

Some vocabulary, in plain terms. Compounding is when a licensed pharmacy makes a customised medicine for an individual patient, rather than dispensing a mass-manufactured product. Section 503A of the federal food and drug law is the part that governs those pharmacies. A bulk drug substance is the raw active ingredient itself, the powder before it becomes a preparation. For an ingredient with no approved-drug status and no official quality monograph, a pharmacy may only use it if the FDA has put it on this list.

So the practical question is: can a compounding pharmacy legally make these, on a prescription, for a named patient? That is a much narrower question than "are peptides legal" or "do peptides work", and it is emphatically not the same as FDA approval. An approved drug has cleared large trials proving it is safe and effective for a specific use. Nothing on the 503A list has done that. Being listed means the agency has decided the ingredient is acceptable for a pharmacist to work with, not that it has been proven to help anyone.

It is also worth being clear about the direction of risk. All seven were already taken off the FDA's Category 2 list, the "significant safety risk" bucket, in April 2026. That removal is what made this review possible. A favourable vote could open a new legal channel, but an unfavourable one does not close an existing one.

What the FDA's own reviewers concluded before the meeting

Ahead of the meeting, FDA reviewers published briefing documents recommending against adding all seven. Their consistent finding was a lack of human evidence: no human clinical studies at all for KPV, TB-500 and MOTS-c, and only small or poorly controlled ones for the rest.

This part genuinely has already happened, and it is the single most useful thing to know going in. In the briefing materials published for the meeting, the agency's career scientists reached the same conclusion for every one of the seven: do not add it to the list [4]. That is unusual enough to be worth sitting with, because it means the meeting opened with the FDA's own reviewers on record against the entire agenda.

Their stated reasons fall into three groups. The first is missing human evidence. Reviewers found no human clinical studies supporting the proposed uses of KPV, TB-500 or MOTS-c, and only small or poorly controlled studies for BPC-157, emideltide and semax [5]. Most of what exists across all seven is animal work, which tells you a compound is worth studying, not that it works in people.

That gap is visible in the published literature too. A 2025 systematic review of BPC-157 in orthopaedic sports medicine gathered 36 studies and found that 35 of them were preclinical, with a single clinical study among them [6]. This is a peptide with a large and enthusiastic following and almost no human trial base underneath it.

The second group is product quality: inadequate characterisation of the substances, inconsistent naming across suppliers, and missing quality data. The third is safety, including unassessed immunogenicity risk, adverse event reports filed for BPC-157, and the fact that TB-500 and MOTS-c are both prohibited by the World Anti-Doping Agency, which matters directly to any competing athlete [5].

A briefing document is a recommendation to the committee, not a decision. The committee is free to disagree with it, and the votes scheduled across these two days are precisely where that happens.

Who is in the room

The FDA replaced much of the roster in June, and the published roster lists nineteen voting members. Reporting found at least seven with financial ties to the peptide industry, and noted that the eight temporary members the agency added, mostly academic, provided most of the margin that carried the yes votes.

A committee that might vote against its own agency's scientists is only as credible as its independence, which is why its composition has drawn as much attention as the evidence.

The FDA overhauled the roster in June 2026 [7]. Reporting on the panel found that at least seven members had financial connections to the field, including owners of wellness clinics that sell peptides, operators of pharmacies that produce them, and online consulting businesses [8]. The agency's own published roster for this meeting bears out the shape of that: of the eleven standing voting members, nine list a clinic, pharmacy or health-business affiliation as their primary role [9].

The roster also shows something the headline number misses. Alongside the standing members sit eight temporary voting members, drawn largely from universities, the Veterans Health Administration and patient-advocacy groups, and several are seated for one peptide only: a USC liver specialist for BPC-157, a Georgetown dermatologic surgeon for KPV and TB-500, a Weill Cornell neurologist and a VA pain director for semax [9]. The panel that votes on BPC-157 is therefore not the same panel that votes on semax.

None of that predetermines any outcome, and industry experience is not automatically disqualifying: people who work with these compounds often understand them best. But it is a reasonable thing for a reader to weigh. When a panel is asked whether a market should be expanded, and part of the panel operates in that market, the recommendation carries an asterisk that a purely academic panel's would not. It is fair to hold that thought and still take the evidence discussion seriously.

How this meeting came about

The Health Secretary has publicly championed peptides. In February 2026 he announced that about fourteen of the nineteen peptides on the restricted list would move back, the FDA removed twelve from Category 2 in April, and this review is the next step in that sequence.

This review did not appear from nowhere, and the sequence behind it is entirely in the past, so it can be stated plainly.

Robert F. Kennedy Jr., the Health and Human Services Secretary, has been openly supportive of expanding peptide access and has described himself as a "big fan" [8]. On February 27, 2026 he announced that roughly fourteen of the nineteen peptides that had been moved to Category 2 would be moved back, on the argument that the reclassification had been improper [3]. The FDA's action removing twelve peptides from Category 2 followed in April 2026, and the Federal Register notice that scheduled this meeting and opened its public docket published on April 16, 2026 [10], which is what put these seven in front of an advisory committee.

The politics are worth naming plainly because they explain the shape of the disagreement. This is not the usual pattern of an agency responding to new clinical trial results. It is a policy push meeting a scientific record that has not changed much, which is exactly why the FDA's reviewers and the department's leadership have ended up on opposite sides of the same meeting. Readers can support wider access and still notice that the evidence base has not grown.

What changes for you right now

Nothing changed on the day of the vote. The committee only recommends, the FDA decides afterwards, and any listing then goes through formal rulemaking, which takes time. No pharmacy changed what it can legally make when the panel voted, and research-chemical sales are untouched either way.

The honest answer is nothing, yet, and being clear about that is more useful than the headline that the panel "backed" these peptides.

The committee's votes are recommendations. The FDA reviews them and decides independently, and it can accept, modify or reject what the panel advised [1]. Adding a substance to the 503A list then runs through formal rulemaking, a public notice-and-comment process that commonly takes many months. No pharmacy's legal position changed the moment the panel voted, and none of these peptides became legal to compound or approved as a drug that day.

What that means in practice: a vial sold today labelled "for research use only" is not affected by any of this. That market sits outside the compounding system entirely, and it is where the real day-to-day risk lives, because the FDA's quality concerns in these briefing documents were about characterisation and consistency of the raw substance. Those concerns apply with far more force to material bought from an unregulated supplier than to anything a licensed pharmacy would make. If you take one practical thing from this proceeding, let it be that the agency's reviewers spent as much time on what is actually in the vial as on whether the compound works.

If you want to understand how to evaluate a supplier and read a certificate of analysis, that is a genuinely useful skill regardless of how these votes land, and it is worth more than following the regulatory news.

What to watch next

The votes are cast, so the next steps are the FDA's own decision, then formal rulemaking if it agrees. A second meeting before the end of February 2027 takes up five more peptides, including GHK-Cu, melanotan II, dihexa and cathelicidin, better known as LL-37.

With the votes recorded, three things follow from here.

First, the FDA decides. The agency weighs the recommendations against its own review, and its reviewers said no to all seven in writing, so the committee handed it a visible split it now has to resolve in public. That decision, not the advisory vote, is what would actually change any peptide's legal status.

Second, rulemaking. Even for the six the panel backed, adding a substance to the 503A list runs through a formal notice-and-comment process that commonly takes several months to well over a year. So "the panel voted yes" and "you can legally get this from a compounding pharmacy" are separated by a real regulatory gap, and anyone counting on the second because of the first is getting ahead of the process.

Third, a second meeting comes before the end of February 2027, covering five more: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor [3]. Several of those have a longer research history than the seven decided this week, so the evidence discussion should look different.

Underneath all of it, the tension does not resolve. Demand for these compounds is enormous and the human evidence is thin, and no vote changes either fact. The strongest argument for expanding legal compounding is that restriction pushes people toward an unregulated grey market of overseas suppliers; the strongest argument against is that a pharmacy channel implies a level of validation that these compounds have not earned. Both can be true at once, which is why this has been contested for years and will stay contested after the votes are counted.